Table 1.
Selected clinical trials of combination therapy or multi-target immunotherapy.
| Clinical Trials | Agents | Format | Status |
|---|---|---|---|
| Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM (Phase 1, NCT03706547) | BCMA/CD19 CAR-T | CAR-T | Active, not recruiting |
| Anti-BCMA or/and Anti-CD19 CART Cells Treatment of Relapsed Multiple Myeloma (Phase 1, NCT03767725) | BCMA/CD19 CAR-T | CAR-T | Recruiting |
| Targeting CD19 and BCMA CAR-T Cells Immunotherapy in Patients with Relapsed or Refractory Multiple Myeloma (Phase 1+2, NCT04714827) | BCMA/CD19 CAR-T | CAR-T | Recruiting |
| A New Study Evaluating the Activity of Modular CAR T for mYeloma (MCARTY) (Phase 1, NCT04795882) | BCMA/CD19 CAR-T | CAR-T | Recruiting |
| A Feasibility and Safety Study of Dual Specificity CD38 and BCMA CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma (Phase 1+2, NCT03767751) | BCMA/CD38 CAR-T | CAR-T | Recruiting |
| BCMA-CS1 Compound CAR (cCAR) T Cells for Relapsed/Refractory Multiple Myeloma (Phase 1, NCT04156269) | BCMA-CS1 cCAR T | CAR-T | Recruiting |
| Safety and Efficiency Study of BCMA-PD1-CART Cells in Relapsed/Refractory Multiple Myeloma (Phase 2, NCT04162119) | BCMA-PD1-CART | CAR-T | Recruiting |
| BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma (Phase 1, NCT04162353) | BCMA-CD19 cCAR | CAR-T | Recruiting |
| A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma (Phase 1, NCT04182581) | BCMA/CD19 CAR-T | CAR-T | Recruiting |
| Humanized CAR-T Cells of Anti-BCAM and Anti-CD19 Against Relapsed and Refractory Multiple Myeloma (Phase 1, NCT04194931) | BCMA/CD19 CAR-T | CAR-T | Recruiting |
| A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory MM (Phase 1, NCT04412889) | BCMA/CD19 CAR-T | CAR-T | Recruiting |
| Up-front CART-BCMA with or without huCART19 in High-risk Multiple Myeloma (Phase 1, NCT03549442) | CART-BCMA, huCART19 | CAR-T | Recruiting |
| Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High-Risk Multiple Myeloma Followed with Auto-HSCT (Phase 1+2, NCT03455972) | BCMA/CD19 CAR-T | CAR-T | Recruiting |
| CAR-T Cells Combined with Dasatinib for Patients with Relapsed and/or Refractory B-cell Hematological Malignancies (Phase 1, NCT04603872) | BCMA/CD19 CAR-T | CAR-T | Recruiting |
| A Feasibility and Safety Study of Dual Specificity CD38 and BCMA CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma (Phase 1/2, NCT03767751) | CD38/BCMA CAR-T | CAR-T | Recruiting |
| BCMA-CS1 Compound CAR (cCAR) T Cells for Relapsed/Refractory Multiple Myeloma (Phase 1, NCT04156269) | BCMA-CS1 CAR-T | CAR-T | Recruiting |
| Study of T Cells Targeting CD138/BCMA/CD19/More Antigens (CART-138/BCMA/19/More) for Chemotherapy Refractory and Relapsed Multiple Myeloma (Phase 1, NCT03196414) | Multiple targets | CAR-T | Recruiting |
The status of each trial is based on the description on the Clinicaltrials.gov website by 20 October 2021.